SMC-101-017

SMC-101-017 is a small molecule dual inhibitor of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) and Tyrosine Kinase with Immunoglobulin-like and EGF-like domains 2 (TIE2). Developed by researchers at Samsung Medical Center using a fragment-recombination design approach, the compound is intended for the treatment of sarcomas. In preclinical studies, SMC-101-017 demonstrated potent, time-dependent cytotoxicity against human osteosarcoma cell lines (including 143B and KHOS/NP) while maintaining selectivity by sparing myeloid cells (RAW264.7). This profile distinguishes it from approved multi-kinase inhibitors like pazopanib and regorafenib, which showed lower potency or reduced selectivity in the same models.